The Role of Maresin1 and Maresin2 Serum Levels in Prediction of Prognosis in Thrombectomised ischemic Stroke Patients

English (OpenAlex)

Objective: Although endovascular treatment (EVT) is widely accepted as the standard approach for acute ischemic stroke (IS), the prognostic determinants are not yet fully clarified. This study was designed to investigate the prognostic value of serum Maresin-1 (MaR1) and Maresin-2 (MaR2) levels in IS patients treated with EVT.Method: In this prospective study at Dicle University Faculty of Medicine, Department of Neurology, Stroke Center, 59 IS patients undergoing EVT and 24 healthy controls were enrolled between March 1 and August 1, 2024. Serum levels of MaR1, MaR2, albumin, hemoglobin A1C, neutrophils, platelets, lipid profile, vitamin D, C-reactive protein, and ferritin were measured. Clinical data included baseline NIHSS, 3-month mRS, TICI recanalization, and pre-stroke comorbidities. Multivariable logistic regression analyses were performed to evaluate associations between MaR1, MaR2, stroke severity, and mortality.Results: MaR1 and MaR2 concentrations were markedly reduced in the ischemic stroke group compared with healthy controls (p = 0.04 and p = 0.02). In parsimonious multivariable logistic regression analyses for 3-month mortality, neither MaR1 nor MaR2 showed an independent association, although both demonstrated borderline relationships after adjustment for age and baseline NIHSS. In contrast, stroke severity analysis revealed that higher MaR1 levels were independently associated with increased stroke severity (OR = 2.123; 95% CI, 1.18–3.25; p = 0.047), whereas MaR2 was not. Additionally, lower serum albumin levels emerged as an independent predictor of greater stroke severity in both models.Conclusions: These findings suggest that MaR1 may reflect stroke severity rather than mortality, while albumin represents a key systemic determinant of disease severity. Maresins appear to act as inflammation-related biomarkers whose prognostic effects are modulated by overall metabolic and inflammatory status.